AIVITA Biomedical CEO Dr. Hans Keirstead Leads Multidisciplinary Team of Scientists Invited by Dalai Lama to Discuss Consciousness
IRVINE, Calif. – Oct. 25, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that CEO Hans Keirstead, Ph.D., led a team of eminent scientists to meet with the 14th Dalai Lama, by his invitation, for a multidisciplinary exploration of the scientific evidence of consciousness. In their meeting, the parties contemplated neuroscience, medically recorded near-death experiences, quantum and theoretical physics, reincarnation, medically recorded out-of-body experiences, and the scientific evidence of mind-spirit benefit to health. The discussion explored whether any evidence exists from the various scientific domains to support a model of consciousness, and whether consciousness could reside outside of the human body.
The visiting participants were Hans Keirstead, Ph.D., renowned neuroscientist, and developer of numerous human cell therapies; Sir Roger Penrose, Ph.D., Nobel Laureate and renowned mathematical quantum physicist and one of the world’s leading experts on black holes and quantum physics; Peter Fenwick, M.D., neuropsychiatrist, neurophysiologist, and one of the leading authorities in the scientific study of end-of-life phenomena; Adrian Kent, Ph.D., a quantum physicist at the University of Cambridge and a leading expert in theoretical relationships in quantum physics and entanglement; Olaf Blanke, Ph.D., a professor and world leader in the neurological basis of self-consciousness and investigator of out-of-body experiences through fMRI; and Wayne Jonas, M.D., an integrative health expert who has investigated the impact of spirituality on medical research and practice.
Dr. Keirstead’s efforts in organizing this expedition exemplify his global thought leadership and AIVITA’s ongoing commitment to global science advocacy. Excerpts from these discussions will be published at a future date.
About AIVITA Biomedical
Founded in 2016 by pioneers in the cell therapy industry, AIVITA Biomedical, Inc. utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline. Our cancer immunotherapy targets the seed of all cancers, tumor-initiating cells, with a unique pan-antigenic approach that targets all neoantigens specific to the patient’s cancer. Our patient-specific cancer treatments have shown tremendous promise including eradicating tumors, without harmful side effects in melanoma, and renal cell cancer, and prolonging progression-free survival in glioblastoma. Our COVID-19 Vaccine Enabling Kit is targeted to emerging nations enabling point-of-care vaccine production in minimally equipped facilities by minimally-trained third-party technicians.
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on a number of assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.